ASRT Earnings Prediction
The chart below shows how ASRT performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ASRT sees a -4.05% change in stock price 10 days leading up to the earnings, and a -1.32% change 10 days following the report. On the earnings day itself, the stock moves by +0.16%. This data can give you a slight idea of what to expect for the next quarter's release.
ASRT Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
29.20M
-18.03%
-6.17%
Gross Margin
51.30%
-0.58%
2.58%
Operating Margin
-9.41%
-14.84%
-19.02%
Net Margin
-10.00%
-98.73%
-15.25%
EPS
-0.03
-99.12%
-25.00%
No Data Available
ASRT Earnings Analysis
Assertio Holdings, Inc. Common Stock Corporation (ASRT.O) Earnings Conference Call
Positive
R&D Expense Stability: R&D expense in the third quarter was relatively flat at approximately $1 million.
Adjusted Operating Expense Decline: On an adjusted basis, excluding stock compensation, D&A and change in fair value, adjusted operating expense was $16.4 million in the third quarter, down from $17.7 million in the second quarter.
Gross Margin Improvement: Reported gross margin in the third quarter improved to 74%, compared to 71% in the second quarter, primarily due to level of inventory step-up amortization and write-downs from prior quarter, not repeating.
Q3 Adjusted EBITDA Increase: Q3 adjusted EBITDA was a positive $5.3 million, increased from $5 million in the second quarter due to lower operating expenses, partially offset by lower product sales.
Cash Position Stability: Total cash at the end of the quarter was $88.6 million, effectively flat to the $88.4 million in the second quarter and debt remained unchanged at $40 million.
Negative
Product Sales Decline: Total product sales were $28.7 million, down slightly from $30.7 million in the second quarter, primarily due to ROLVEDON sales being offset by the expected decline in INDOCIN.
Quarterly Sales Comparison: ROLVEDON sales were $15 million in the third quarter compared to $15.1 million in the second quarter.
INDOCIN Sales Decline: INDOCIN sales were $5.7 million in the third quarter, down from $6.9 million in the second quarter, driven by lower net pricing as a result of generic competition.
Quarterly Net Income Loss: GAAP net income for the third quarter was a loss of $2.9 million, down from a loss of $3.7 million in the second quarter.
Operating Expense Reduction: Adjusted operating expense was $16.4 million in the third quarter, down from $17.7 million in the second quarter, primarily due to lower sales and marketing and other G&A costs.
ASRT FAQs
How does ASRT typically perform around its earnings report dates?
Is Assertio Holdings, Inc. (ASRT) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
ASRT Earning Call Sentiment
Assertio Holdings, Inc. (ASRT) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
ASRT.O
-2.83%Positive
The earnings call highlights mixed signals: slight improvement in gross margin and adjusted EBITDA, but declining sales due to generic competition and market dynamics. The lack of a shareholder return plan and unchanged guidance suggest limited immediate upside. The Q&A reveals uncertainty in pricing and growth, with vague management responses. These factors, combined with legal and leadership challenges, suggest a neutral outlook for short-term stock price movement.